Birchview Capital’s Grace Therapeutics GRCE Stock Holding History

Birchview Capital’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$232K	Buy	+50,000	New	+$196K	0.13%	66

Other funds holding GRCE

Cerity Partners New York $70.8B AUM 21.68% 1-Year Est. Return

Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

CCM

Connective Capital Management Palo Alto, California $121M AUM 39.82% 1-Year Est. Return

Birchview Capital's GRCE Position: Q1 2026 in Review

Birchview Capital opened a new position in Grace Therapeutics (GRCE) in Q1 2026: 50,000 shares worth $232K. The stake represents 0.13% of the portfolio and ranks #66 among its holdings.

34 funds tracked by Wall St. Rank hold GRCE as of Q1 2026.

Birchview Capital held 50,000 shares of Grace Therapeutics worth $232K as of Q1 2026.
Grace Therapeutics was a new Birchview Capital position in Q1 2026.
Grace Therapeutics made up 0.13% of Birchview Capital's portfolio in Q1 2026, its #66 holding.
34 funds tracked by Wall St. Rank held Grace Therapeutics as of Q1 2026.

Based on Birchview Capital's 13F filing for Q1 2026, filed 15 May 2026.